LBA21 InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5 fluorouracil (5 FU) vs carboplatin (C) plus weekly …

Background: Whilst advanced squamous cell carcinoma of the anal canal (SCCA) is a rare disease incidence has risen by 2%/year for the past decade. There is no consensus on management of these pts who generally have a poor overall survival (OS) and to date no randomised trial has been completed. The combination of fluoropyrimidine/platinum agents is often considered standard 1st line therapy whilst taxanes have shown activity. We conducted a randomised phase II study to establish a standard of care.Methods: Eligible pts randomised in 1: 1 ratio to CDDP (60 mg/m 2, D1q21)/5-FU (1000 mg/m 2/24h, D1-4q21) or C (AUC...